# Article information:

Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401) | Antibodies | News Channels  
<https://pipelinereview.com/index.php/2021073078862/Antibodies/Late-Breaking-AAIC-Presentation-Explores-Potential-Clinical-Effects-Of-Lecanemab-BAN2401.html>

# Article summary:

1. Eisai and Biogen presented preliminary assessment of the clinical effects of Lecanemab (BAN2401) following 18 months of treatment in the open-label extension of the Phase 2 proof-of-concept study at the Alzheimer's Association International Conference.

2. Lecanemab is an investigational humanized monoclonal antibody that preferentially binds to soluble amyloid-beta (Aβ) aggregates (protofibrils), and it may suggest a potential disease-modifying effect.

3. The results support the concept of increased long-term benefit of continued treatment with Lecanemab when initiated in the early AD stage, and these preliminary findings are being further evaluated in the ongoing Phase 3 Clarity AD study for early AD.

# Article rating:

Appears moderately imbalanced: The article provides some useful information, but is missing several important points or pieces of evidence that would be required to present the discussed topics in a balanced and reliable way. You are encouraged to seek a more balanced perspective on the presented issues by exploring the provided research topics and looking at different information sources.

# Article analysis:

作为一篇新闻报道，该文章提供了关于 Eisai 和 Biogen 公司在 Alzheimer's Association International Conference 上展示的针对早期阿尔茨海默病患者的临床试验结果的简要概述。然而，该文章存在以下问题：

1. 偏见来源：该文章没有提及任何可能存在的偏见来源，例如资助方或作者自身的利益冲突。

2. 片面报道：该文章只报道了正面结果，并没有探讨任何负面结果或不确定性。

3. 无根据的主张：该文章声称 lecanemab 可能具有疾病修复效应，但并没有提供足够的证据来支持这一主张。

4. 缺失考虑点：该文章没有探讨任何可能存在的风险或副作用，也没有考虑到其他治疗方法和替代方案。

5. 主张缺失证据：尽管该文章声称 lecanemab 在临床试验中表现出良好的效果，但并没有提供足够的证据来支持这一主张。

6. 未探索反驳：该文章没有探讨任何可能存在的反驳观点或争议点。

7. 宣传内容：该文章似乎更像是一篇宣传稿件，而不是客观报道。它强调了 Eisai 公司采用“精准医学”方法开发新解决方案，并引用了公司高管和首席临床官 Lynn Kramer 的话语来支持其立场。

8. 偏袒：尽管 Biogen 是本次临床试验合作伙伴之一，但该文章似乎更倾向于 Eisai 公司，并忽略了 Biogen 的角色和贡献。

总之，这篇报道缺乏客观性和全面性，并可能受到资助方或作者自身利益冲突等偏见影响。读者需要谨慎对待其中所述内容，并寻找更多信息以进行综合评估。

# Topics for further research:

* Potential bias sources
* One-sided reporting
* Unsupported claims
* Missing considerations
* Lack of evidence for claims
* Unexplored counterarguments

# Report location:

<https://www.fullpicture.app/item/7e7c490b8c7f706f23e194540ba5ee27>